Your Plan Covers One GLP-1 and Not the Other: What Now

The short answer

This is normal, it is a contracting outcome rather than a clinical judgment about you, and you have three moves. Take the covered drug, request a formulary exception for the one you were prescribed, or pay cash for the second. Which one is right depends less on the medicine than on your calendar and your prescriber's read of your history.

What it is not is a verdict on whether the drug you wanted works. Plans build formularies around indications and negotiated arrangements, and two products can be treated very differently on the same drug list.

Why a plan pays for one and not the other

Coverage keys to the approved use. The two labels do not carry identical indications:

• Wegovy is indicated to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight; to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 and older with obesity, and in adults with overweight plus at least one weight-related comorbid condition; and for noncirrhotic MASH with moderate to advanced fibrosis¹.
• Zepbound is indicated to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight with at least one weight-related comorbid condition, and to treat moderate to severe obstructive sleep apnea in adults with obesity².

So a plan that pays for one prescription and refuses another may be paying for a different indication, not a different molecule. If you carry a diagnosis that appears on one label and not the other, that is the sentence your prescriber should be putting in the request.

Beyond indications, formularies simply exclude things. In a national all-payer study of more than two million first fill attempts for single-source branded drugs, 14.8% were rejected for formulary exclusion and 17.2% for prior authorization or step therapy, and formulary-based rejections rose from 24.3% in 2018 to 40.7% in 2024³.

What switching actually costs you

Each product has its own label-specified starting dose and titration interval, and switching means running the covered product's schedule from its own beginning.

Those are label figures, not advice — your prescriber decides your schedule, including whether any of it can be shortened. The practical point for a working mother is that a switch is measured in months of appointments and side-effect adjustment, not in one pharmacy trip. That is a real cost, and it belongs in the decision.

The three moves, and when each one wins

• Take the covered drug. Usually the right call when you have not started yet, your prescriber has no clinical objection, and the covered product's label covers your diagnosis. The cheapest month is the one the plan pays for.
• Request a formulary exception. Right when there is a documented clinical reason — a prior trial of the covered product that failed or was not tolerated, a contraindication, or a diagnosis that only the requested product's label carries. The paragraph for this is template 5 in our denial-reason appeal letters.
• Pay cash for the one you want. Right when you are already stable on it and restarting a titration would cost you more than the money does. Price it honestly against your covered cost share in insurance vs cash-pay: the real monthly math.

The four questions to ask before you decide

1. 1.Which product does the plan cover, at what tier, and with what prior authorization criteria?
2. 2.Does my diagnosis appear on the covered product's label, or only on the other one?
3. 3.Is there a documented history — a failed trial, an intolerance, a contraindication — that supports an exception?
4. 4.What does the exception process require, and how long does it take?

Question two is the one people skip and the one that most often wins. Question four sets your calendar: a pre-service claim must be decided within 15 days, extendable once by 15, and you have at least 180 days to file an internal appeal if it is denied⁴.

If you are mid-treatment

Do not stop a working treatment because a coverage letter arrived. Ask your prescriber to submit the exception request while you are still supplied, and read hold, drop, or push through for how dose interruptions actually play out. If the switch is happening anyway, Zepbound vs Wegovy compares the two head to head, and the pill versus the shot for a working week matters if the covered option is oral.

The decisive takeaway

A plan covering one GLP-1 and not another is usually telling you about indications and formulary contracts, not about your medicine. Check whether your diagnosis sits on the covered product's label, weigh the months a fresh titration costs against the money, and if there is a documented clinical reason for the one you were prescribed, file the exception rather than accepting the substitution by default. If neither route works, our cheapest GLP-1 board prices the cash lane and the board for busy schedules ranks it on the time it costs you. Some links here earn us a referral fee, which never changes the ranking.